Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Free Radic Biol Med. 2019 Nov 7;146:181–188. doi: 10.1016/j.freeradbiomed.2019.10.414

Fig. 6.

Fig. 6.

Systemic administration of CPUY192018 confers retinal neuroprotection in ischemia-reperfusion injury. (A) Schematic diagram of CPUY192018 administration and OKT assay in rats subjected to ischemia-reperfusion injury. (B) Spatial frequency measured by OKT testing following ischemia-reperfusion injury was improved by systemic administration of CPUY192018 (10 mg/kg) through systemic administration. (C) Spatial frequency was similarly improved by treatment with the triterpenoid Nrf2 activator CDDO-Me (1.5 mg/kg), used as a positive control. Values shown are mean ± SD (n = 6). *, p < 0.05.